NASDAQ:OMGA Omega Therapeutics (OMGA) Stock Price, News & Analysis → Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad) Free OMGA Stock Alerts $2.31 -0.05 (-2.12%) (As of 03:04 PM ET) Add Compare Share Share Today's Range$2.22▼$2.4550-Day Range$1.96▼$4.3352-Week Range$1.30▼$10.09Volume373,575 shsAverage Volume1.58 million shsMarket Capitalization$127.40 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Omega Therapeutics alerts: Email Address Omega Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside338.6% Upside$10.00 Price TargetShort InterestBearish22.04% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.56Based on 21 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.30) to ($1.19) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.76 out of 5 starsMedical Sector679th out of 928 stocksBiological Products, Except Diagnostic Industry113th out of 153 stocks 3.5 Analyst's Opinion Consensus RatingOmega Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOmega Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Omega Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted22.04% of the float of Omega Therapeutics has been sold short.Short Interest Ratio / Days to CoverOmega Therapeutics has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.Change versus previous monthShort interest in Omega Therapeutics has recently increased by 1.58%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldOmega Therapeutics does not currently pay a dividend.Dividend GrowthOmega Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OMGA. Previous Next 2.0 News and Social Media Coverage News SentimentOmega Therapeutics has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Omega Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for OMGA on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Omega Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -11% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Omega Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders57.00% of the stock of Omega Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.47% of the stock of Omega Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Omega Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Omega Therapeutics are expected to grow in the coming year, from ($1.30) to ($1.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Omega Therapeutics is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Omega Therapeutics is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOmega Therapeutics has a P/B Ratio of 3.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Omega Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Market Moving TrendsTop 5 AI Stocks to Buy for 20245 Best AI Stocks to Invest In Investors are getting very rich in AI stocks right now. Wall Street legend is giving away the name and ticker of the little-known AI stock Wall Street is currently buying hand-over-fist.Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In" About Omega Therapeutics Stock (NASDAQ:OMGA)Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Read More OMGA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OMGA Stock News HeadlinesMay 15 at 6:12 AM | americanbankingnews.comBrokers Set Expectations for Omega Therapeutics, Inc.'s Q3 2025 Earnings (NASDAQ:OMGA)May 15 at 3:38 AM | americanbankingnews.comOmega Therapeutics (NASDAQ:OMGA) Stock Rating Reaffirmed by HC WainwrightMay 13 at 5:58 PM | markets.businessinsider.comBuy Rating Reaffirmed for Omega Therapeutics on Strong Clinical and Financial PerformanceMay 12 at 3:50 AM | americanbankingnews.comAnalysts Set Expectations for Omega Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:OMGA)May 9, 2024 | americanbankingnews.comQ2 2024 Earnings Estimate for Omega Therapeutics, Inc. Issued By Wedbush (NASDAQ:OMGA)May 9, 2024 | americanbankingnews.comChardan Capital Reiterates "Buy" Rating for Omega Therapeutics (NASDAQ:OMGA)May 8, 2024 | globenewswire.comOmega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic ControllersMay 8, 2024 | americanbankingnews.comOmega Therapeutics (NASDAQ:OMGA) Stock Rating Reaffirmed by WedbushMay 7, 2024 | markets.businessinsider.com4 Analysts Have This To Say About Omega TherapeuticsMay 7, 2024 | finance.yahoo.comOmega Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS In LineMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Omega Therapeutics Amid Strong Financials and Promising OTX-2002 Clinical TrialsMay 6, 2024 | markets.businessinsider.comOmega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company ProgressMay 6, 2024 | investorplace.comOMGA Stock Earnings: Omega Therapeutics Misses EPS, Beats Revenue for Q1 2024May 6, 2024 | globenewswire.comOmega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company ProgressApril 23, 2024 | globenewswire.comOmega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual MeetingApril 9, 2024 | globenewswire.comOmega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic ControlMarch 31, 2024 | seekingalpha.comOmega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy'March 29, 2024 | finance.yahoo.comWe Think Omega Therapeutics (NASDAQ:OMGA) Needs To Drive Business Growth CarefullyMarch 29, 2024 | investorplace.comOMGA Stock Earnings: Omega Therapeutics Beats EPS, Beats Revenue for Q4 2023March 28, 2024 | globenewswire.comOmega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic UpdateMarch 16, 2024 | finance.yahoo.comOMGA Apr 2024 12.500 callMarch 12, 2024 | markets.businessinsider.comIntrommune Therapeutics Strengthens Board of Directors with Appointments of Dr. Jonathan Rich and Hem PandyaMarch 6, 2024 | globenewswire.comOmega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024January 26, 2024 | benzinga.comHow Is The Market Feeling About Omega Therapeutics?January 16, 2024 | seekingalpha.comOmega Therapeutics: The Next Weight Loss Drug RunnerSee More Headlines Receive OMGA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Omega Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today5/15/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:OMGA CUSIPN/A CIK1850838 Webwww.omegatherapeutics.com Phone617-949-4360FaxN/AEmployees93Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$12.00 Low Stock Price Target$7.00 Potential Upside/Downside+323.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-97,430,000.00 Net Margins-1,868.35% Pretax Margin-1,868.35% Return on Equity-136.04% Return on Assets-44.21% Debt Debt-to-Equity Ratio0.34 Current Ratio2.87 Quick Ratio2.87 Sales & Book Value Annual Sales$3.09 million Price / Sales42.12 Cash FlowN/A Price / Cash FlowN/A Book Value$1.05 per share Price / Book2.25Miscellaneous Outstanding Shares55,150,000Free Float23,717,000Market Cap$130.15 million OptionableOptionable Beta1.99 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Mahesh Karande (Age 50)President, CEO & Board Director Comp: $812.88kMs. Ling Zeng Esq. (Age 54)J.D., Chief Legal & Administrative Officer and Secretary Comp: $519.36kDr. Yan Moore M.D. (Age 57)Chief Medical Officer Comp: $1.14MMr. Joshua Reed M.B.A. (Age 50)Chief Financial Officer Key CompetitorsMolecular PartnersNASDAQ:MOLNKaryopharm TherapeuticsNASDAQ:KPTIScilexNASDAQ:SCLXaTyr PharmaNASDAQ:LIFEBioAtlaNASDAQ:BCABView All CompetitorsInstitutional OwnershipVanguard Group Inc.Sold 229,263 shares on 5/10/2024Ownership: 2.321%View All Institutional Transactions OMGA Stock Analysis - Frequently Asked Questions Should I buy or sell Omega Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Omega Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OMGA shares. View OMGA analyst ratings or view top-rated stocks. What is Omega Therapeutics' stock price target for 2024? 4 Wall Street analysts have issued 12 month target prices for Omega Therapeutics' stock. Their OMGA share price targets range from $7.00 to $12.00. On average, they expect the company's share price to reach $10.00 in the next year. This suggests a possible upside of 338.6% from the stock's current price. View analysts price targets for OMGA or view top-rated stocks among Wall Street analysts. How have OMGA shares performed in 2024? Omega Therapeutics' stock was trading at $3.01 at the beginning of the year. Since then, OMGA stock has decreased by 24.3% and is now trading at $2.28. View the best growth stocks for 2024 here. When is Omega Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our OMGA earnings forecast. How were Omega Therapeutics' earnings last quarter? Omega Therapeutics, Inc. (NASDAQ:OMGA) posted its quarterly earnings data on Thursday, March, 28th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.09. The firm had revenue of $0.99 million for the quarter, compared to analysts' expectations of $0.93 million. Omega Therapeutics had a negative trailing twelve-month return on equity of 136.04% and a negative net margin of 1,868.35%. When did Omega Therapeutics IPO? Omega Therapeutics (OMGA) raised $126 million in an initial public offering on Friday, July 30th 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. Who are Omega Therapeutics' major shareholders? Omega Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.32%). Insiders that own company stock include Flagship Pioneering Inc and Richard A Young. View institutional ownership trends. How do I buy shares of Omega Therapeutics? Shares of OMGA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OMGA) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersBill Clinton Backing Biden Replacement???The Freeport Societyis this a buy and hold stock?Tips4TradersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaTrump Reveals Conspiracy Behind Fed-Controlled Digital Currency.Monetary GoldTop 5 Tech Stocks to Buy for 2024Daily Market AlertsTop 5 AI Stocks to Buy for 2024Market Moving TrendsWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks News[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omega Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
